2025’s Therapy Area Growth Drivers And Brakes: Part Three

The final instalment of In Vivo’s three-part series delves into the therapeutic categories that will propel forecast pharmaceutical sales growth for 2025, focusing on mood disorders, immunodeficiency, viral infections, and blood cell disorders.

Foot pedals are levers of forklift car that are activated by the driver's feet to control certain aspects of the vehicle's operation brake pedal Car accelerator controls. - Image
• Source: Shutterstock

As described in part one of this series, the chart below shows expected sales differences between 2024 and 2025 grouped by therapeutic category. The leading drivers of growth have been singled out – as have those areas that are expected to undergo the largest sales contraction. It should be noted that this analysis only includes forecasts where covering analysts have assigned specific indications for the sales. 

Of the total estimated net growth of $72bn, the top 10 therapeutic areas are expected to contribute over 73% of...

More from Growth

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.